


PHARMACEUTICAL 2022

Ensysce Biosciences Inc. Rank 437 of 475











Ensysce Biosciences Inc. Rank 437 of 475

The relative strengths and weaknesses of Ensysce Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ensysce Biosciences Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 127% points. The greatest weakness of Ensysce Biosciences Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 310% points.

The company's Economic Capital Ratio, given in the ranking table, is -621%, being 345% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	15,663
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,482
Liabilities, Non-Current	8,094
Other Assets	755
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-9,275
Property and Equipment	0
Research and Development	4,690
Revenues	3,531
Selling, General and Administrative Expense	18,712

Output Variable	Value in 1000 USD
Assets	16,417
Liabilities	24,575
Expenses	23,402
Stockholders Equity	-8,158
Net Income	-29,146
Comprehensive Net Income	-29,146
Economic Capital Ratio	-621%

